

## OUR PIPELINE

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

PROGRAM	PHASE 1	PHASE 2	PHASE 3
<b>BRENTUXIMAB VEDOTIN<sup>1</sup></b> <span data-bbox="1052 562 1078 590">●</span> <span data-bbox="1230 562 1256 590">●</span> <span data-bbox="1409 562 1435 590">●</span>			
<b>DESCRIPTION</b> CD30 Antibody Drug Conjugate	<b>DISEASE(S) UNDER INVESTIGATION</b> Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma		
<hr/>			
<b>BRIGATINIB</b> <span data-bbox="1052 963 1078 991">●</span> <span data-bbox="1230 963 1256 991">●</span> <span data-bbox="1409 963 1435 991">●</span>			
<b>DESCRIPTION</b> ALK Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Non-small Cell Lung Cancer		
<hr/>			
<b>IXAZOMIB</b> <span data-bbox="1052 1365 1078 1392">●</span> <span data-bbox="1230 1365 1256 1392">●</span> <span data-bbox="1409 1365 1435 1392">●</span>			
<b>DESCRIPTION</b> Proteasome Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Multiple Myeloma, Amyloidosis		

PROGRAM	PHASE 1	PHASE 2	PHASE 3
---------	---------	---------	---------

**PEVONEDISTAT**



**DESCRIPTION**  
Nedd8-Activating Enzyme Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia

**PEVONEDISTAT**



**DESCRIPTION**  
Nedd8-Activating Enzyme Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Solid Tumors

**PONATINIB<sup>2</sup>**



**DESCRIPTION**  
BCR-ABL Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Chronic Myeloid Leukemia

**PONATINIB<sup>2</sup>**



**DESCRIPTION**  
BCR-ABL Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

PROGRAM

PHASE 1

PHASE 2

PHASE 3

**SAPANISERTIB (TAK-228)**



**DESCRIPTION**

TORC1/TORC2 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Endometrial Cancer

**SAPANISERTIB (TAK-228)**



**DESCRIPTION**

TORC1/TORC2 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Solid Tumors

**TAK-659**



**DESCRIPTION**

SYK/FLT-3 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Lymphoma, Acute Myelogenous Leukemia

**TAK-659**



**DESCRIPTION**

SYK/FLT-3 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Solid Tumors

PROGRAM

PHASE 1

PHASE 2

PHASE 3

TAK-931



**DESCRIPTION**

CDC7 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Pancreatic Cancer, Colorectal Cancer

TAK-931



**DESCRIPTION**

CDC7 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Solid Tumors

CABOZANTINIB<sup>3</sup>



**DESCRIPTION**

MET, VEGF, AXL and RET Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Renal Cell Carcinoma

VEDOLIZUMAB



**DESCRIPTION**

Anti- $\alpha$ 4 $\beta$ 7 Antibody

**DISEASE(S) UNDER INVESTIGATION**

Graft versus Host Disease

PROGRAM

PHASE 1

PHASE 2

PHASE 3

**NIRAPARIB<sup>4</sup>**



**DESCRIPTION**  
PARP Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Ovarian Cancer

**TAK-522 (XMT-1522)<sup>5</sup>**



**DESCRIPTION**  
HER2 Dolaflexin Antibody Drug Conjugate

**DISEASE(S) UNDER INVESTIGATION**  
Breast Cancer

**TAK-788 (AP32788)**



**DESCRIPTION**  
EGFR/HER2 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Non-small Cell Lung Cancer

**TAK-573**



**DESCRIPTION**  
CD38-targeted IgG4 fused with attenuated IFN $\alpha$

**DISEASE(S) UNDER INVESTIGATION**  
Multiple Myeloma

PROGRAM

PHASE 1

PHASE 2

PHASE 3

TAK-164



**DESCRIPTION**

Anti-guanlyl cyclase C antibody drug conjugate

**DISEASE(S) UNDER INVESTIGATION**

Pancreatic Cancer, Colorectal Cancer

Last updated 2018-05-10

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. 2 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). 3 Japan Only. 4 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. 5 Ex-U.S., Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc.



ONCOLOGY

©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.  
All rights reserved. 04/18